This is a Phase 2, single arm, open-label, multicenter study evaluating the feasibility of a treatment regimen comprised of nivolumab administered approximately every 2 weeks before and during chemoradiation and as an adjuvant therapy for 3 months to patients with stage II-IVB NPC who are planning to undergo chemoradiation treatment of their cancer.